Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology of diabetes in Iran: A scoping review of studies published during 2015–2019

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Background

Proper synthesis of existing epidemiologic studies on diabetes in Iran can guide future research efforts. We aimed to conduct a comprehensive scoping review on all research articles that investigated any aspect of diabetes epidemiology in Iran during 2015–2019.

Methods

This work was conducted as a part of the Iran Diabetes Research Roadmap and completed under Arksey and O'Malley’s framework for scoping reviews. The Scopus and PubMed databases were searched on Feb 15th, 2020. Eligible document types on diabetes epidemiology in the Iranian population, in Persian or English, that published during the 2015–2019 period underwent eligibility assessment. A total of 315 relevant articles were included and further analysis was performed on the original studies (n = 268). Through classifying them into six domains: Diabetes incidence; the prevalence of diabetes and associated factors; the incidence/prevalence of complications/comorbid conditions; mortality/survival; burden; and prediction modeling.

Results

In total, 64 (20.3%) papers were published in Q1 journals, and 40 (12.6%) were international collaborations. No clear annual trend was present in the number of published primary or secondary articles, the portion of papers published in Q1 journals, international collaborations or relative domain proportions. Few review articles were found on prediction modeling, mortality or burden (excluding global studies).

Conclusions

Our findings show a minor portion of works on diabetic epidemiology in Iran meets the quality standards of Q1 journals. Researchers have neglected some critical subjects and have occasionally fallen for common pitfalls of epidemiologic research. In particular, adhering to established guidelines can help authors implement rigorous methods to develop, validate, and deploy practical clinical prediction models. Researchers should prioritize investigating longitudinally collected data that aid in measuring disease incidence and enable casual inference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328(23):1676–85.

    Article  CAS  PubMed  Google Scholar 

  2. Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2020: 108086.

  3. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.

  4. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–49.

    Article  PubMed  Google Scholar 

  5. Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al . US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2016;67(3 Suppl 1): Svii, S1-305.

  6. Djalalinia S, Modirian M, Sheidaei A, Yoosefi M, Zokaiee H, Damirchilu B, et al. Protocol Design for Large-Scale Cross-Sectional Studies of Surveillance of Risk Factors of Non-Communicable Diseases in Iran: STEPs 2016. Arch Iran Med. 2017;20(9):608–16.

    PubMed  Google Scholar 

  7. Aguiree F, Brown A, Cho N, Dahlquist G, Aguiree B, Cho D, et al. Whiting (2013) IDF Diabetes Atlas. IDF Diabetes Atlas, 6th Edition, International Diabetes Federation, Basel.74–90.

  8. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.

  9. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.

    Article  Google Scholar 

  11. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.

    Article  PubMed  Google Scholar 

  12. Süt N. Study designs in medicine. Balkan Med J. 2014;31(4):273.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, 2020.

  14. Zand A, Ibrahim K, Patham B. Prediabetes: Why Should We Care? Methodist Debakey Cardiovasc J. 2018;14(4):289–97.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015;6(6):850.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kriegsman DM, Penninx BW, Van Eijk JTM, Boeke AJP, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly: a study on the accuracy of patients’ self-reports and on determinants of inaccuracy. J Clin Epidemiol. 1996;49(12):1407–17.

    Article  CAS  PubMed  Google Scholar 

  17. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157: 107843.

    Article  PubMed  Google Scholar 

  18. Goldman N, Lin I-F, Weinstein M, Lin Y-H. Evaluating the quality of self-reports of hypertension and diabetes. J Clin Epidemiol. 2003;56(2):148–54.

    Article  PubMed  Google Scholar 

  19. Spronk I, Korevaar JC, Poos R, Davids R, Hilderink H, Schellevis FG, et al. Calculating incidence rates and prevalence proportions: not as simple as it seems. BMC Public Health. 2019;19(1):1–9.

    Article  Google Scholar 

  20. Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010;126(6):2234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(Suppl 1):S144–50.

    Article  PubMed  Google Scholar 

  22. Schooling CM, Jones HE. Clarifying questions about “risk factors”: predictors versus explanation. Emerg Themes Epidemiol. 2018;15(1):1–6.

    Article  Google Scholar 

  23. Craun GF, Calderon RL. How to interpret epidemiological associations. Nutrients in Drinking Water. 2005;108:108–15.

    Google Scholar 

  24. Abbasi SH, Sundin Ö, Jalali A, Soares J, Macassa G. Ethnic differences in the risk factors and severity of coronary artery disease: a patient-based study in Iran. J Racial Ethn Health Disparities. 2018;5(3):623–31.

    Article  PubMed  Google Scholar 

  25. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr DiabRep. 2013;13(6):814–23.

    Google Scholar 

  26. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost—consequence analysis in healthcare decision—making. Pharmacoeconomics. 1998;13(3):277–88.

    Article  CAS  PubMed  Google Scholar 

  28. Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AM, et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ. 2012;345:e5900.

  29. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346:e5595.

  30. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) the TRIPOD statement. Circulation. 2015;131(2):211–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest. 2012;42(2):216–28.

    Article  PubMed  Google Scholar 

  32. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for some traditional and novel measures. Epidemiology. 2010;21(1):128.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Steyerberg EW, Harrell FE Jr. Prediction models need appropriate internal, internal-external, and external validation. J Clin Epidemiol. 2016;69:245.

    Article  PubMed  Google Scholar 

  34. Bleeker S, Moll H, Steyerberg E, Donders A, Derksen-Lubsen G, Grobbee D, et al. External validation is necessary in prediction research: A clinical example. J Clin Epidemiol. 2003;56(9):826–32.

    Article  CAS  PubMed  Google Scholar 

  35. Van Calster B, McLernon DJ, Van Smeden M, Wynants L, Steyerberg EW. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):1–7.

    Google Scholar 

  36. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio) marker. Heart. 2012;98(9):683–90.

    Article  PubMed  Google Scholar 

  37. Steyerberg, EW. Selection of main effects. In: Steyerberg, EW, editors. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Springer International Publishing; 2019. p. 207–225.

  38. Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012;98(9):691–8.

    Article  PubMed  Google Scholar 

  39. Shafiee G, Nasli-Esfahani E, Bandarian F, Peimani M, Yazdizadeh B, Razi F, et al. Iran Diabetes Research Roadmap (IDRR): the study protocol. J Diabetes Metab Disord. 2016;15:58.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Esmaeili S, Bandarian F, Razi F, Adibi H, Jalili A, Arjmand B, et al. An overview of diabetes research achievements during a quarter of a century in Diabetes Research Center. J Diabetes Metab Disord. 2021;1–8.

Download references

Acknowledgements

The authers would like to express their gratitude to all the researchers and personell at the Endocrinology and Metabolism Research Institute who supported the conduct of this work.

Author information

Author notes

  1. Fatemeh Gharishvandi and Hamed Moheimani contributed equally to this work.

  2. Ensieh Nasli-Esfahani and Noushin Fahimfar are co- Corresponding Authors who contributed equally to this manuscript.

Authors and Affiliations

  1. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, PO Box: 1411413137, Tehran, Iran

    Fatemeh Gharishvandi, Shahnaz Esmaeili, Ali Tootee & Ensieh Nasli Esfahani

  2. Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Hamed Moheimani & Noushin Fahimfar

  3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Bagher Larijani

Authors
  1. Fatemeh Gharishvandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamed Moheimani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shahnaz Esmaeili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bagher Larijani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ali Tootee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ensieh Nasli Esfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noushin Fahimfar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ensieh Nasli Esfahani or Noushin Fahimfar.

Ethics declarations

Ethical approval

The research protocol and ethical conduct for Iran Diabetes Research Roadmap were approved by the Endocrinology and Metabolism Research Institute at Tehran University of Medical Sciences (Code: IR.TUMS.EMRIEC,1399.004).

a project numbered 1398–1-97–974 approved by the Endocrinology and Metabolism Research Institute, Tehran University of Medical Silences.

The Ethics Committee of Tehran University of Medical Sciences approved the present study with the approval number of IR. TUMS.EMRIREC. 1399.004.

Competing interests

None declared.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 50 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gharishvandi, F., Moheimani, H., Esmaeili, S. et al. Epidemiology of diabetes in Iran: A scoping review of studies published during 2015–2019. J Diabetes Metab Disord 21, 1913–1921 (2022). https://doi.org/10.1007/s40200-022-01094-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-022-01094-0

Keywords

Search

Navigation